AbbVie to Strengthen Neuroscience Pipeline with $8.7 Billion for Cerevel Therapeutics
AbbVie and Cerevel Therapeutics announced that AbbVie will buy Cerevel Therapeutics and its neuroscience pipeline of schizophrenia, Parkinson's disease, and mood disorder drugs that are in multiple clinical and preclinical…